"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Patients should be advised:
- that grepafloxacin may be taken with or without meals.
- that grepafloxacin increases the effects of theophylline, and to advise their physician immediately if they are taking theophylline.
- that multivitamins (containing iron or zinc), antacids, (containing magnesium, calcium, or aluminum), sucralfate, or VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 4 hours before or 4 hours after taking grepafloxacin (see DRUG INTERACTIONS ).
- that grepafloxacin may increase the effects of other drugs metabolized by the liver, and to advise their physician of any of the drugs they are taking.
- to drink fluids liberally.
- that grepafloxacin may increase the effects of caffeine.
- that grepafloxacin may be associated with hypersensitivity reactions, even following a single dose, and to discontinue the drug at the first sign of skin rash, hives, or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, or any other symptom of an allergic reaction (see WARNINGS ).
- that grepafloxacin may cause dizziness and lightheadedness; therefore, patients should know how they react to this drug before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination.
- to discontinue treatment; rest and refrain from exercise; and to contact their physician immediately if they experience pain, inflammation or rupture of a tendon .
- to avoid excessive sunlight or artificial ultraviolet light while taking grepafloxacin and to discontinue therapy if phototoxicity (e.g., sunburn-like reaction or skin eruptions) occurs.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Raxar Information
Report Problems to the Food and Drug Administration
Find out what women really need.